GeneDx Holdings (WGS) Current Deferred Revenue (2020 - 2022)

GeneDx Holdings has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $40000.0 for Q4 2022.

• In Q4 2022, Current Deferred Revenue fell 91.54% year-over-year to $40000.0; the TTM figure through Dec 2022 stood at $40000.0 (down 91.54% YoY), while the FY2022 annual figure was $40000.0, down 91.54% from the prior year.
• Current Deferred Revenue slipped to $40000.0 in Q4 2022, from $100000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for WGS reached as high as $2.8 million in Q1 2021 and fell as low as $40000.0 in Q4 2022.
• The 3-year median for Current Deferred Revenue is $493000.0 (2021), against an average of $1.0 million.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue tumbled 73.72% — and 2022, when it plunged 96.44%.
• A 3-year view of Current Deferred Revenue shows it stood at $1.8 million in 2020, then plunged by 73.72% to $473000.0 in 2021, then sank by 91.54% to $40000.0 in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $40000.0, $100000.0, and $473000.0 for Q4 2022, Q1 2022, and Q4 2021 respectively.